Westpac Banking Corp Sells 2,859 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Westpac Banking Corp reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 53.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,452 shares of the biopharmaceutical company’s stock after selling 2,859 shares during the period. Westpac Banking Corp’s holdings in Alnylam Pharmaceuticals were worth $811,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. MV Capital Management Inc. acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $29,000. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $27,000. Golden State Wealth Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 36 shares during the period. Finally, Manchester Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 72 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $266.99 on Thursday. The firm has a market cap of $35.65 billion, a P/E ratio of 72.95 and a beta of 0.27. Alnylam Pharmaceuticals, Inc. has a 52-week low of $264.21 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The business’s fifty day moving average is $293.02 and its 200-day moving average is $317.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.44) earnings per share. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALNY. Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Citigroup started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective for the company. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 7th. Finally, Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $452.13.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.